Header

UZH-Logo

Maintenance Infos

DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus


Rasmussen, Robert A; Hofmann-Lehmann, Regina; Montefiori, D C; Li, P L; Liska, V; Vlasak, J; Baba, T W; Schmitz, J E; Kuroda, M J; Robinson, H L; McClure, H M; Lu, S; Hu, S L; Rizvi, T A; Ruprecht, Ruth M (2002). DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. Journal of Medical Primatology, 31(1):40-60.

Abstract

Newborn macaques were vaccinated against a chimeric simian human immunodeficiency (SHIV) virus, SHIV-vpu+, by DNA priming and boosting with homologous HIV-1 gp160. Following SHIV-vpu+ challenge, containment of infection was observed in 4 of 15 animals given DNA priming/protein boost vaccination and in three of four animals given gp160 boosts only. Rechallenge with homologous virus of six animals that contained the first challenge virus resulted in rapid viral clearance or low viral loads. Upon additional rechallenge with heterologous, pathogenic SHIV89.6P, four of these six animals maintained normal CD4+ T-cell counts with no or limited SHIV89.6P infection. Our data suggest that humoral and cellular immune mechanisms may have contributed to the containment of SHIV89.6P; however, viral interference with SHIV-vpu+ could also have played a role. Our results indicate that immunogenicity and efficacy of candidate AIDS vaccines are not affected when vaccination is initiated during infancy as compared with later in life.

Abstract

Newborn macaques were vaccinated against a chimeric simian human immunodeficiency (SHIV) virus, SHIV-vpu+, by DNA priming and boosting with homologous HIV-1 gp160. Following SHIV-vpu+ challenge, containment of infection was observed in 4 of 15 animals given DNA priming/protein boost vaccination and in three of four animals given gp160 boosts only. Rechallenge with homologous virus of six animals that contained the first challenge virus resulted in rapid viral clearance or low viral loads. Upon additional rechallenge with heterologous, pathogenic SHIV89.6P, four of these six animals maintained normal CD4+ T-cell counts with no or limited SHIV89.6P infection. Our data suggest that humoral and cellular immune mechanisms may have contributed to the containment of SHIV89.6P; however, viral interference with SHIV-vpu+ could also have played a role. Our results indicate that immunogenicity and efficacy of candidate AIDS vaccines are not affected when vaccination is initiated during infancy as compared with later in life.

Statistics

Citations

25 citations in Web of Science®
31 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

0 downloads since deposited on 05 Dec 2016
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Veterinary Clinic > Department of Farm Animals
Dewey Decimal Classification:570 Life sciences; biology
630 Agriculture
Language:English
Date:February 2002
Deposited On:05 Dec 2016 12:52
Last Modified:11 Dec 2016 06:20
Publisher:Wiley-Blackwell Publishing, Inc.
ISSN:0047-2565
Publisher DOI:https://doi.org/10.1034/j.1600-0684.2002.1o019.x
PubMed ID:12076047

Download